John A. Flatt, MD

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA · Full program

• PosterThe Safety and Effect of Ecopipam During the First 8 Weeks of Tourette’s Disorder Treatment: A Post-Hoc Analysis

  October 28, 2026, 13:00–15:00

  Post-hoc analysis of the safety and effects of ecopipam over the first 8 weeks of treatment in Tourette's disorder.

  Autism & Neurodevelopmental DisordersChild & AdolescentDrug Pipeline & Clinical Trials

• PosterLong-Term Safety and Effect of Ecopipam, a Selective Dopamine D1 Receptor Antagonist, in Children, Adolescents, and Adults With Tourette's Disorder

  October 28, 2026, 13:00–15:00

  Reports long-term safety and efficacy of the D1 antagonist ecopipam in Tourette's disorder across children, adolescents and adults.

  Autism & Neurodevelopmental DisordersChild & AdolescentDrug Pipeline & Clinical Trials

• PosterThe Presence of Common Psychiatric Diagnoses Did Not Impact the Efficacy or Safety of Ecopipam in Individuals With Tourette’s Disorder

  October 28, 2026, 13:00–15:00

  Analyzes whether co-occurring psychiatric diagnoses affected ecopipam efficacy or safety in people with Tourette's disorder.

  Autism & Neurodevelopmental DisordersChild & AdolescentDrug Pipeline & Clinical Trials